With choice of PrEP products on the horizon – including oral PrEP, the PrEP ring, and CAB PrEP – PrEP marketing and demand generation must evolve with the availability of new PrEP products. Young people, in particular, need PrEP demand generation campaigns tailored to their needs and aspirations.
Continue Reading
Three MTN studies – REACH, DELIVER, and B-PROTECTED – recently published critical new data on PrEP ring use among adolescent girls and young women (AGYW), pregnant individuals, and breastfeeding individuals in Africa. All studies offer compelling evidence that the ring is safe for use among these populations.
Continue Reading
Expanding access to and uptake of PrEP products among young people, especially adolescent girls and young women, will be key to ending the HIV epidemic. But how do we ensure HIV prevention efforts resonate with and are effective for young millennials and Gen Z? What does meaningful youth engagement in PrEP delivery really mean?
Continue Reading
This IAS 2023 session will review evidence from recent studies designed to inform CAB PrEP introduction in Asia; identify regional priorities for a CAB implementation science agenda; examine regional lessons from oral PrEP introduction and scale-up; highlight progress and lessons from preparing for CAB rollout in Africa; and introduce available policy and program planning tools and resources to help countries prepare for CAB rollout.
Continue Reading
MOSAIC is heading to Durban, South Africa, for the 11th SA AIDS conference. This year’s conference theme: Act, connect, and end the epidemic. We invite conference attendees to join us for the following sessions.
Continue Reading
As new PrEP products move out of clinical trials and toward market entry, implementation research has a pivotal role to play in guiding the introduction and scale-up of these new products in real-world service delivery settings.
Continue Reading
New products, including the dapivirine vaginal ring and injectable cabotegravir, have been approved in several countries, and more biomedical prevention products are in development. As the catalog of HIV prevention products expands, so too does the conversation about the importance of upholding choice to optimize the benefits for potential PrEP users.
Continue Reading
We know that adolescent girls and young women live complex lives full of important relationships that shape the decisions they make. Yet too often efforts to generate demand for PrEP fail to reach beyond the individual user to her support system—those trusted people in her life who she leans on when making important choices. But demand generation for PrEP is evolving.
Continue Reading
Since oral PrEP was first approved for use in 2012, dozens of countries have approved the product and use is expanding. But the pace of scale-up has been slower than expected and PrEP remains out of reach for many who may benefit from it.
Continue Reading
This workshop will explore what is needed to ensure that introductory research and programs are strategically designed, user-centered, and appropriately resourced to support successful rollout of CAB PrEP.
Continue Reading